Judith L. Kirstein

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017 · 813 citations

Obesity, Metabolic Syndrome, Nutrition +8

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

Timo Vesikari, Joanne M. Langley, Nathan Segall et al. · The Lancet Infectious Diseases · 2021 · 70 citations

Vaccination, Vaccine Safety, Viral Hepatitis +8

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial

Timo Vesikari, Judith L. Kirstein, Grace Devota Go et al. · The Lancet Respiratory Medicine · 2018 · 65 citations

Vaccination, Vaccinology, Vaccine Safety +11

Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

Richard Rupp, Gary J. Luckasen, Judith L. Kirstein et al. · Vaccine · 2015 · 64 citations · Full text

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study

Judith L. Kirstein, Miriam Pina, Judy Pan et al. · Human Vaccines & Immunotherapeutics · 2020 · 24 citations · Full text

Immunodeficiencies, Immunology, Immunodominance +17